vs
Side-by-side financial comparison of Neptune Insurance Holdings Inc. (NP) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $37.8M, roughly 1.5× Neptune Insurance Holdings Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 28.8%).
Neptune Insurance Holdings Inc. is a specialty insurance holding company that offers a broad portfolio of property and casualty insurance products, with a core focus on residential and commercial flood insurance for customers across the United States. It serves both individual consumers and small to mid-sized business clients, using advanced data analytics to support accurate policy pricing and robust risk management.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
NP vs PHAT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.8M | $57.6M |
| Net Profit | $50.0K | — |
| Gross Margin | — | 86.7% |
| Operating Margin | — | — |
| Net Margin | 0.1% | — |
| Revenue YoY | 28.8% | 94.1% |
| Net Profit YoY | 0.0% | 71.6% |
| EPS (diluted) | $0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $37.8M | — | ||
| Q4 25 | — | $57.6M | ||
| Q3 25 | $44.4M | $49.5M | ||
| Q2 25 | — | $39.5M | ||
| Q1 25 | — | $28.5M | ||
| Q4 24 | — | $29.7M | ||
| Q3 24 | $33.8M | $16.4M | ||
| Q2 24 | — | $7.3M |
| Q1 26 | $50.0K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $11.5M | $-30.0M | ||
| Q2 25 | — | $-75.8M | ||
| Q1 25 | — | $-94.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $12.1M | $-85.6M | ||
| Q2 24 | — | $-91.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | — | 81.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 46.7% | -30.8% | ||
| Q2 25 | — | -151.7% | ||
| Q1 25 | — | -276.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 58.6% | -433.0% | ||
| Q2 24 | — | -1055.4% |
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 25.9% | -60.5% | ||
| Q2 25 | — | -191.9% | ||
| Q1 25 | — | -330.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 35.8% | -523.3% | ||
| Q2 24 | — | -1248.6% |
| Q1 26 | $0.05 | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $0.06 | $-0.41 | ||
| Q2 25 | — | $-1.05 | ||
| Q1 25 | — | $-1.31 | ||
| Q4 24 | — | — | ||
| Q3 24 | $0.06 | $-1.32 | ||
| Q2 24 | — | $-1.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $130.0M |
| Total DebtLower is stronger | — | $209.1M |
| Stockholders' EquityBook value | — | $-438.2M |
| Total Assets | — | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $130.0M | ||
| Q3 25 | $12.2M | $135.2M | ||
| Q2 25 | — | $149.6M | ||
| Q1 25 | — | $212.3M | ||
| Q4 24 | — | $297.3M | ||
| Q3 24 | — | $334.7M | ||
| Q2 24 | — | $276.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $209.1M | ||
| Q3 25 | $247.6M | $207.1M | ||
| Q2 25 | — | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-438.2M | ||
| Q3 25 | $-509.5M | $-422.5M | ||
| Q2 25 | — | $-405.8M | ||
| Q1 25 | — | $-338.4M | ||
| Q4 24 | — | $-253.6M | ||
| Q3 24 | $-374.3M | $-187.1M | ||
| Q2 24 | — | $-233.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | $259.1M | ||
| Q3 25 | $89.6M | $240.3M | ||
| Q2 25 | — | $250.2M | ||
| Q1 25 | — | $294.2M | ||
| Q4 24 | — | $378.3M | ||
| Q3 24 | — | $387.0M | ||
| Q2 24 | — | $319.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-166.8M |
| Free Cash FlowOCF − Capex | — | $-167.0M |
| FCF MarginFCF / Revenue | — | -290.0% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-166.8M | ||
| Q3 25 | $38.9M | $-14.1M | ||
| Q2 25 | — | $-62.7M | ||
| Q1 25 | — | $-84.9M | ||
| Q4 24 | — | $-266.8M | ||
| Q3 24 | — | $-63.6M | ||
| Q2 24 | — | $-70.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-167.0M | ||
| Q3 25 | — | $-14.1M | ||
| Q2 25 | — | $-62.8M | ||
| Q1 25 | — | $-84.9M | ||
| Q4 24 | — | $-266.9M | ||
| Q3 24 | — | $-63.6M | ||
| Q2 24 | — | $-70.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | -290.0% | ||
| Q3 25 | — | -28.6% | ||
| Q2 25 | — | -159.0% | ||
| Q1 25 | — | -297.9% | ||
| Q4 24 | — | -899.8% | ||
| Q3 24 | — | -389.0% | ||
| Q2 24 | — | -966.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 3.38× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
